ENTITY

Myriad Genetics (MYGN US)

20
Analysis
Health CareUnited States
Myriad Genetics, Inc. develops and markets molecular diagnostic products to provide physicians with information to help guide the care of their patients, to prevent disease, delay the onset of disease, or catch disease at an early stage.
more
16 Dec 2024 17:46

DNA Synthesis with a Silicon Twist

Twist's fast, cheap DNA synthesis will power biotech start-ups, driving demand, fostering loyalty, enabling innovation, and securing new and...

Logo
223 Views
Share
bullishS&P 500 INDEX
10 Aug 2022 06:18

S&P 500, Nasdaq 100 Testing Key Resistance Levels; Pause Likely; Buying Biotech

$SPX is testing important resistance in the 4165-4180 area, the same resistance level we were monitoring in early June before the market tumbled 13...

Logo
325 Views
Share
bullishS&P 500 INDEX
10 Feb 2021 10:34

U.S. Equity Strategy: Bullish Outlook Intact

The action we are seeing in broad indexes, Sectors, and in market dynamics continues to support our overall bullish outlook. Continue to buy dips.

Logo
231 Views
Share
bullishQiagen N.V.
21 Jul 2020 20:02

Qiagen/Thermo Fisher: Qiagen Gets a Bump – Is It Enough to Satisfy Shareholders?

QIAGEN NV (QIA GY) shares have gone from strength to strength with the stock trading above terms and then receiving a bump bid late last week....

Logo
451 Views
Share
bullishPersonalis Inc
18 Jun 2019 17:18

Personalis IPO: Personalising Cancer Trials and Treatments; Upside from Growth in Cancer Market

Personalis offers genomic sequencing to bio-pharmaceutical companies by fully analyzing sample tissue data of cancer patients. It provides its...

Share
x